Nurix Therapeutics (NRIX) Assets Average (2020 - 2026)

Nurix Therapeutics (NRIX) has reported Assets Average for 7 consecutive years, with $585.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Assets Average fell 2.89% year-over-year to $585.8 million; the TTM figure through May 2026 stood at $585.8 million (down 2.89% YoY), while the FY2025 annual figure was $678.7 million, up 32.44% from the prior year.
• Assets Average fell to $585.8 million in Q2 2026 per NRIX's latest filing, from $662.1 million in the prior quarter.
• Across five years, Assets Average topped out at $662.1 million in Q1 2026 and bottomed at $329.4 million in Q3 2023.
• Historically, Assets Average has averaged $481.0 million across 5 years, with a median of $447.6 million in 2022.
• Annual changes were most pronounced in 2023 — Assets Average decreased 24.23% — and 2025, when it soared 92.2%.
• Nurix Therapeutics' Assets Average stood at $438.0 million in 2022, then dropped by 24.23% to $331.9 million in 2023, then soared by 78.21% to $591.5 million in 2024, then advanced by 2.34% to $605.3 million in 2025, then declined by 3.22% to $585.8 million in 2026.
• Business Quant data shows NRIX's Assets Average at $585.8 million in Q2 2026, $662.1 million in Q1 2026, and $605.3 million in Q4 2025.